Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7 expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer

J Biol Chem. 2017 Sep 29;292(39):16321-16332. doi: 10.1074/jbc.M117.793752. Epub 2017 Aug 16.

Abstract

The syndecan family of heparan sulfate proteoglycans contributes to cell adhesion and communication by serving as co-receptors for cell signaling and extracellular matrix molecules. Syndecan-2 is located at the cell surface, and we previously reported that it induces matrix metalloproteinase-7 (MMP-7) expression in colon cancer cells. However, the underlying regulatory mechanisms are unknown. Here, we report that overexpression of syndecan-2 in HT-29 colon cancer cells increases the phosphorylation of focal adhesion kinase (FAK) and ERK in parallel with up-regulated MMP-7 expression, but a syndecan-2 mutant lacking the cytoplasmic domain showed significant reductions in these effects. Consistent with this observation, FAK inhibition via FAK-related non-kinase expression or inhibition of ERK with the ERK1/2 inhibitor SCH772984 diminished the syndecan-2-mediated up-regulation of MMP-7. Activation of PKC enhanced syndecan-2-mediated MMP-7 expression, whereas inhibition of PKC had the opposite effect. Of note, the exogenous expression of syndecan-2 triggered localization of PKCγ to the membrane. Expression of syndecan-2 harboring a phosphomimetic (S198E) mutation of the variable region of the cytoplasmic domain enhanced MMP-7 expression and FAK phosphorylation. Finally, experimental suppression of shedding of the syndecan-2 extracellular domain did not significantly affect the syndecan-2-mediated up-regulation of MMP-7 in the early period after syndecan-2 overexpression. Taken together, these findings suggest that syndecan-2's cytoplasmic domain up-regulates MMP-7 expression in colon cancer cells via PKCγ-mediated activation of FAK/ERK signaling.

Keywords: PTK2 protein tyrosine kinase 2 (PTK2) (focal adhesion kinase) (FAK); extracellular signal-regulated kinase (ERK); matrix metalloproteinase (MMP); protein kinase C (PKC); receptor protein serine/threonine kinase; receptor regulation; signal transduction; syndecan.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Carcinoma / drug therapy
  • Carcinoma / enzymology
  • Carcinoma / metabolism*
  • Colonic Neoplasms / drug therapy
  • Colonic Neoplasms / enzymology
  • Colonic Neoplasms / metabolism*
  • Enzyme Induction / drug effects
  • Focal Adhesion Kinase 1 / chemistry
  • Focal Adhesion Kinase 1 / genetics
  • Focal Adhesion Kinase 1 / metabolism*
  • Humans
  • MAP Kinase Signaling System* / drug effects
  • Matrix Metalloproteinase 7 / genetics
  • Matrix Metalloproteinase 7 / metabolism
  • Mutation
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / chemistry
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Peptide Fragments / antagonists & inhibitors
  • Peptide Fragments / chemistry
  • Peptide Fragments / genetics
  • Peptide Fragments / metabolism
  • Phosphorylation / drug effects
  • Protein Interaction Domains and Motifs
  • Protein Kinase C / metabolism*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Processing, Post-Translational* / drug effects
  • RNA Interference
  • Rats
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / metabolism
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / metabolism
  • Syndecan-2 / antagonists & inhibitors
  • Syndecan-2 / chemistry
  • Syndecan-2 / genetics
  • Syndecan-2 / metabolism*

Substances

  • Neoplasm Proteins
  • Peptide Fragments
  • Protein Kinase Inhibitors
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Sdc2 protein, rat
  • Syndecan-2
  • protein kinase C gamma
  • Focal Adhesion Kinase 1
  • PTK2 protein, human
  • Protein Kinase C
  • MMP7 protein, human
  • Matrix Metalloproteinase 7